Comparative efficacy of immune checkpoint inhibitor-based regimens versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma stratified by etiology: a systematic review and meta-analysis
{{output}}
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with limited treatment success in advanced stages. Tyrosine kinase inhibitors (TKIs), such as sorafenib and lenvatinib, are... ...
